Editorial

Split Viewer

Blood Res 2015; 50(1):

Published online March 31, 2015

https://doi.org/10.5045/br.2015.50.1.1

© The Korean Society of Hematology

Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia

Rojin Park, M.D.

Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

  1. Cines, DB, Bussel, JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood, 2005;106;2244-2251.
    Pubmed
  2. Saleh, MN, Bussel, JB, Cheng, G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 2013;121;537-545.
    Pubmed
  3. Cheng, G. Eltrombopag, a thrombopoietin-receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol, 2012;3;155-164.
    Pubmed
  4. McMillan, R, Wang, L, Tomer, A, Nichol, J, Pistillo, J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood, 2004;103;1364-1369.
    Pubmed
  5. Li, J, Yang, C, Xia, Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 2001;98;3241-3248.
    Pubmed
  6. Kuter, DJ, Bussel, JB, Lyons, RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, 2008;371;395-403.
    Pubmed
  7. Nurden, AT, Viallard, JF, Nurden, P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet, 2009;373;1562-1569.
    Pubmed
  8. Bussel, JB, Cheng, G, Saleh, MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med, 2007;357;2237-2247.
    Pubmed
  9. Kim, YK, Lee, SS, Jeong, SH, et al. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res, 2015;50;19-25.
  10. Tomiyama, Y, Miyakawa, Y, Okamoto, S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost, 2012;10;799-806.
    Pubmed

Article

Editorial

Blood Res 2015; 50(1): 1-2

Published online March 31, 2015 https://doi.org/10.5045/br.2015.50.1.1

Copyright © The Korean Society of Hematology.

Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia

Rojin Park, M.D.

Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    References

    1. Cines, DB, Bussel, JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood, 2005;106;2244-2251.
      Pubmed
    2. Saleh, MN, Bussel, JB, Cheng, G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 2013;121;537-545.
      Pubmed
    3. Cheng, G. Eltrombopag, a thrombopoietin-receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol, 2012;3;155-164.
      Pubmed
    4. McMillan, R, Wang, L, Tomer, A, Nichol, J, Pistillo, J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood, 2004;103;1364-1369.
      Pubmed
    5. Li, J, Yang, C, Xia, Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 2001;98;3241-3248.
      Pubmed
    6. Kuter, DJ, Bussel, JB, Lyons, RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, 2008;371;395-403.
      Pubmed
    7. Nurden, AT, Viallard, JF, Nurden, P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet, 2009;373;1562-1569.
      Pubmed
    8. Bussel, JB, Cheng, G, Saleh, MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med, 2007;357;2237-2247.
      Pubmed
    9. Kim, YK, Lee, SS, Jeong, SH, et al. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res, 2015;50;19-25.
    10. Tomiyama, Y, Miyakawa, Y, Okamoto, S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost, 2012;10;799-806.
      Pubmed
    Blood Res
    Volume 59 2024

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download